Device Trial Radar · NCT06229743
Biolinq Safety and Effectiveness Trial
Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
247
Actual
Start
Feb 29, 2024
Primary completion
Jun 10, 2024
Study completion Jun 10, 2024
Sponsor
- Lead sponsor
- Biolinq Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 29, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the safety and effectiveness of the Biolinq MicroArray Intradermal Continuous Glucose Biowearable System, which is intended to be worn for up to five (5) days (up to 120 hours) in adults with diabetes mellitus (DM). Data collected from this study is intended to be used to support commercial marketing application(s) for the intended commercial patient population of non-insulin-users. All participants will be asked to wear the Biolinq System and a commercial CGM comparator for five to seven days while taking fingersticks on a commercial Self-Monitoring Blood Glucose Meter. Throughout the sensor wear all participants will come back to the clinic twice for in-clinic days where venous blood draws and fingersticks will be used to compare glucose measurements to a Lab Analyzer (YSI). At the end of sensor wear subjects will return to the clinic to have the sensors removed and then exit the study.
Conditions
- Diabetes
- Diabetes Mellitus
Interventions
Biolinq SystemDevice
Participants will wear at least one Biolinq Sensor. The estimated glucose value from the Biolinq Sensor will be compared to a YSI 2300 glucose value from venous blood within a 5 minute window (paired samples).
Primary outcomes
What the sponsor says the trial is designed to measure.
- In Target Color Indicator - BlueTime frame: 5 days
- In Target Color Indicator - YellowTime frame: 5 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Advanced Metabolic Care + Research Institute
Escondido, California
Diablo Clinical Research
Walnut Creek, California
Atlanta Diabetes Associates
Atlanta, Georgia
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.